Stockscreener 앱 받기
20.66
2.59%
-0.55
시간 외 거래:
21.20
0.54
+2.61%
전일 마감가:
$21.21
열려 있는:
$20.27
하루 거래량:
770.91K
Relative Volume:
0.77
시가총액:
$1.37B
수익:
$9.98M
순이익/손실:
$-154.08M
주가수익비율:
-8.0078
EPS:
-2.58
순현금흐름:
$-159.66M
1주 성능:
-6.89%
1개월 성능:
-3.14%
6개월 성능:
-8.06%
1년 성능:
-36.84%
1일 변동 폭
$20.10
$21.61
1주일 범위
$20.10
$22.60
52주 변동 폭
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
20.66 | 1.42B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Can volume confirm reversal in Celldex Therapeutics Inc.High Yield Watchlist with Filtered Picks - Newser
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics Inc.’s volatility index tracking explainedForecasting Stock Moves with AI Insights - Newser
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Is Celldex Therapeutics Inc. stock a good hedge against inflationSwing Gain Strategy with Entry Forecast - Newser
Will Celldex Therapeutics Inc. price bounce be sustainableIntraday Movement Recap and Chart Summary - Newser
Celldex Therapeutics Q2 2025 Earnings Miss Estimates, Revenue Falls Short at $0.7 Million - AInvest
Celldex's Strong Financial Position and Promising Pipeline Support Buy Rating Despite Risks - AInvest
Will Celldex Therapeutics Inc. continue its uptrendMonthly Long-Term Market Recap and Summary - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsWeekly Price Target Forecast and Alerts - Newser
Can Celldex Therapeutics Inc. hit a new high this monthLow Risk Trade Timing with Analysis Metrics - Newser
Celldex reports Q2 EPS (85c), consensus (84c) - TipRanks
Celldex Therapeutics: Navigating Short-Term Losses to Unlock Long-Term Value in a High-Stakes Biotech Play - AInvest
Celldex: Q2 Earnings Snapshot - San Antonio Express-News
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $700,000 vs. FactSet Est of $1.0M - MarketScreener
How Celldex Therapeutics Inc. stock performs during market volatilityBreakout Momentum Picks With Protection Outlined - metal.it
Celldex Therapeutics Inc. Charts Flash Early Recovery SignalsLong Hold Safe Return Strategy Reviewed - metal.it
What makes Celldex Therapeutics Inc. stock price move sharplyHigh-yield market plays - Jammu Links News
What drives Celldex Therapeutics Inc. stock priceSuperior return velocity - Jammu Links News
How does Celldex Therapeutics Inc. generate profit in a changing economyExponential return rates - Jammu Links News
Is it the right time to buy Celldex Therapeutics Inc. stockDynamic investment growth - Jammu Links News
What analysts say about Celldex Therapeutics Inc. stockOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Celldex Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is the risk reward ratio of investing in Celldex Therapeutics Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
Should I hold or sell Celldex Therapeutics Inc. stock in 2025Capitalize on strategic market trends - Jammu Links News
Why is Celldex Therapeutics Inc. stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Is Celldex Therapeutics Inc. a good long term investmentTrack high-yield stocks before they peak - Jammu Links News
What are analysts’ price targets for Celldex Therapeutics Inc. in the next 12 monthsUnlock powerful trading signals for profits - Jammu Links News
Does Celldex Therapeutics Inc. stock perform well during market downturnsInvest in stocks with strong fundamentals - Jammu Links News
Celldex Therapeutics Inc. Stock Analysis and ForecastCapitalize on emerging market sectors - Jammu Links News
Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria - The Globe and Mail
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.AI Trend Detection for Entry Timing - Newser
Using R and stats models for Celldex Therapeutics Inc. forecastingFree Safe Entry Stock Watch Suggestions - Newser
Top chart patterns to watch in Celldex Therapeutics Inc.Weekly Entry Signal Based Forecast Tool - Newser
Why Celldex Therapeutics Inc. stock attracts strong analyst attentionRisk-Managed Trade Alerts for Consistency - Newser
What to expect from Celldex Therapeutics Inc. in the next 30 daysFree Top Gaining Picks With Entry Signals - Newser
Celldex Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree High Yield Stock Screening Results - Newser
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight - PR Newswire
What are Celldex Therapeutics Inc. company’s key revenue driversSmart Portfolio Planner For Beginners - Jammu Links News
Visual analytics tools that track Celldex Therapeutics Inc. performanceFree Community Entry Consensus Trade Ideas - Newser
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):